Jci_page_head_homepage_01 Jci_page_head_homepage_02
Anil K. Sood, Guillermo N. Armaiz-Pena, Jyotsnabaran Halder, Alpa M. Nick, Rebecca L. Stone, Wei Hu, Amy R. Carroll, Whitney A. Spannuth, Michael T. Deavers, Julie K. Allen, Liz Y. Han, Aparna A. Kamat, Mian M.K. Shahzad, Bradley W. McIntyre, Claudia M. Diaz-Montero, Nicholas B. Jennings, Yvonne G. Lin, William M. Merritt, Koen DeGeest, Pablo E. Vivas-Mejia, Gabriel Lopez-Berestein, Michael D. Schaller, Steven W. Cole, Susan K. Lutgendorf
Published in Volume 120, Issue 5
J Clin Invest. 2010; 120(5):1515–1523 doi:10.1172/JCI40802
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 6
Clinical significance of FAK activation in ovarian carcinoma.

(A) Representative images of human ovarian tumors with low or high immunohistochemical staining for FAK and pFAKY397. Original magnification, ×200. (B) Kaplan-Meier curves of disease-specific mortality for patients with epithelial ovarian carcinoma based on FAK or pFAKY397 expression. The log-rank test (2-sided) was used to compare differences between groups. Percentage of ovarian cancers with high FAK or pFAKY397 expression based on CESD scores of at least 16 (C) or tumoral norepinephrine (NE) levels (greater versus less than median value of 0.84 pg/mg) (D).